2016 Health Law & Policy Summer Institute Faculty (Tentative)

John T. Boese is a nationally recognized expert on the civil False Claims Act and its unique qui tam enforcement mechanism. He is the author of Civil False Claims and Qui Tam Actions (Wolters Kluwer Law & Business 4th ed.), a comprehensive, two-volume treatise on the civil False Claims Act and qui tam enforcement at both the federal and state levels. This book is cited as authority by courts at all levels—including the United States Supreme Court, eleven US Courts of Appeals, most federal district courts, and many state courts. It was cited by the Securities and Exchange Commission as a source for the SEC's rules on whistleblower awards.

Mr. Boese is of counsel in Fried, Frank, Harris, Shriver & Jacobson's Washington, DC office, where he served as managing partner as well as co-chair of its litigation department for many years. He has represented, and continues to represent, a broad range of defendants in numerous False Claims Act cases brought by qui tam relators or by the Department of Justice. These clients include defense contractors, pharmaceutical companies, construction companies, insurance companies, oil & gas companies, major retailers, import/export firms, computer manufacturers and service providers, hospitals, churches, universities, and airports. He has appeared in over 40 federal district courts, and has argued in most of the US Courts of Appeals.

Daniel Kracov is a partner at Arnold & Porter LLP, where he co-chairs the firm's FDA and Healthcare Practice Group. Mr. Kracov assists clients, including investors, start-up companies, trade associations, and large manufacturing companies, in negotiating the legal requirements relating to the development, approval, and marketing of drugs, biologics, and medical devices. He routinely handles FDA inspections, investigations, and enforcement matters. He also helps clients develop global corporate compliance programs, conducts compliance reviews and audits, and manages regulatory due diligence for financings, mergers and acquisitions. He has a widely-recognized experience in biomedical product-related public policy matters, including Congressional investigations and FDA-related legislative initiatives. His expertise in FDA matters has been recognized by Chambers, the Legal Times, and numerous other publications.

>Prior to joining Pillsbury, Ms. Kung worked as a health care associate for another law firm and specialized in health care law. During law school, she worked at the Department of Health and Human Services - Office for Civil Rights in Atlanta, Georgia conducting legal research on the interaction between HIPAA and state laws and answering questions from the public and health care providers regarding HIPAA privacy.

Asha Scielzo is Law and Government Health Law & Policy Fellow and Adjunct Associate Professor of Law. In this leadership role, Professor Scielzo assists with development of the health law and policy curriculum, recruitment of adjunct professors, expansion of health law externships, career counseling, career panels and other programming. She advises the student-led Health Law & Policy Brief and Health Law & Justice Society. She founded and manages the annual WCL National Health Law Writing Competition and directs the annual Health Law & Policy Summer Institute.

Professor Scielzo also serves in the capacity of Special Counsel in Pillsbury Winthrop Shaw Pittman's Health Care practice, resident in the Washington, DC office. In this role, she concentrates her practice on health care regulatory counseling, with significant expertise in fraud and abuse and reimbursement considerations and their impact on day-to-day operations, corporate compliance and governance, and transactions.